VLDLR Antibody (E-8): sc-390555

VLDLR Antibody (E-8) is a mouse monoclonal IgG1 antibody that detects VLDLR (very low density lipoprotein receptor) in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). VLDLR plays a crucial role in neuronal migration during brain development by mediating the interaction between extracellular Reelin and the cytosolic protein mDab1 (mammalian disabled protein), which activates a downstream tyrosine kinase signaling pathway. This interaction is vital for the proper positioning of neurons along the radial glial fiber network, ensuring the correct formation of neural circuits. The structure of VLDLR, characterized by a cluster of cysteine-rich class A repeats, epidermal growth factor-like repeats, YWTD repeats, and an O-linked sugar domain, is essential for function and stability, as VLDLR facilitates receptor folding and secretion in association with receptor-associated protein (RAP). VLDLR expression in key tissues such as the brain, heart, skeletal muscle, and adipose tissue underscores importance in various physiological processes, making anti-VLDLR antibody (E-8) a valuable tool for researchers studying development and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

VLDLR Antibody (E-8) References:

1. Arginase I and the very low-density lipoprotein receptor are associated with phenotypic biomarkers for obesity.  |  Kim, OY., et al. 2012. Nutrition. 28: 635-9. PMID: 22189190
2. Very low density lipoprotein receptor (VLDLR) expression is a determinant factor in adipose tissue inflammation and adipocyte-macrophage interaction.  |  Nguyen, A., et al. 2014. J Biol Chem. 289: 1688-703. PMID: 24293365
3. Wnting out ocular neovascularization: using nanoparticle delivery of very-low density lipoprotein receptor extracellular domain as Wnt pathway inhibitor in the retina.  |  Busik, JV. and Grant, MB. 2015. Arterioscler Thromb Vasc Biol. 35: 1046-7. PMID: 25903649
4. Functional Differences of Very-Low-Density Lipoprotein Receptor Splice Variants in Regulating Wnt Signaling.  |  Chen, Q., et al. 2016. Mol Cell Biol. 36: 2645-54. PMID: 27528615
5. The association of very low-density lipoprotein receptor (VLDLR) haplotypes with egg production indicates VLDLR is a candidate gene for modulating egg production.  |  Wang, Z., et al. 2016. Genet Mol Biol. 39: 380-91. PMID: 27560838
6. Very low-density lipoprotein receptor increases in a liver-specific manner due to protein deficiency but does not affect fatty liver in mice.  |  Oshio, Y., et al. 2021. Sci Rep. 11: 8003. PMID: 33850206
7. Quantification of soluble very low-density lipoprotein receptor in human serum using a sandwich enzyme-linked immunosorbent assay.  |  Tokita, Y., et al. 2023. Pract Lab Med. 37: e00337. PMID: 37781344
8. Silencing Very-Low-Density Lipoprotein Receptor Reveals Alpha-1 Antitrypsin Role in HIV Infectivity.  |  Bristow, CL. 2024. Methods Mol Biol. 2750: 175-184. PMID: 38108977
9. Very low-density lipoprotein receptor mediates triglyceride-rich lipoprotein-induced oxidative stress and insulin resistance.  |  Hajri, T., et al. 2024. Am J Physiol Heart Circ Physiol. 327: H733-H748. PMID: 38787383
10. The VLDLR entry receptor is required for the pathogenesis of multiple encephalitic alphaviruses.  |  Palakurty, S., et al. 2024. Cell Rep. 43: 114809. PMID: 39369384

The preferred VLDLR antibody is VLDLR Antibody (6A6): sc-18824.